Company Overview and News

8
Weekly Cannabis Report: Tilray Is Damaging The Entire Pot Sector

2018-09-24 seekingalpha - 2
Cannabis stocks continued to show momentum despite a sell-off on Thursday and Friday driven by Tilray's spectacular rise and fall.
SNNVF MJ SHOP EVIO ACBFF MJX BSTI TLRY ACB IIPR HMLSF RDDTF CNTTF APHQF

13
Getting 'High' With A Cannabis-Related Investment In Psychemedics

2018-09-21 seekingalpha
When members of my anti-pharma, anti-tobacco, anti-alcohol stock club suggested investing in cannabis several months ago, I was surprised. So, I promptly found a good reason to stall.
STZ.B WEED RTI PMD RDDTF STZ CGC SMG

11
The Best 'Pick And Shovel' Plays Of Cannabis (Part II)

2018-09-21 seekingalpha - 1
In this article, we will discuss three more companies that all focus on the technologies that can be used in the cannabis industry.
LXX EVIO RTI BSTI RDDTF TLRY LXRP SMG

30
Canadian Legalization: What's Next For Cannabis Stocks?

2018-06-21 seekingalpha
On June 19, 2018, the Canadian Senate passed The Cannabis Act 52 to 29. The rest of the approval process will be completed before the end of the week.
SNNVF KHRNF ACBFF RTI DTK CGC GSK LXX TWMJF ACB WEED RDDTF OGRMF OGI LXRP

 
Weekly Cannabis Report: Aurora/MedReleaf, Canopy, Maricann

2018-05-15 seekingalpha
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis.
CRON RTI RDDTF CCAN MEDFF HMPPF

17
Aurora: Q3 2018, Another Solid Quarter Eclipsed By M&A Rumor

2018-05-10 seekingalpha
Revenue grew 38% driven by other revenue outside cannabis sales, which only increased 11% during the quarter.
TWMJF ACBFF WEED RTI LQSIF APHQF RDDTF CNGGF MEDFF HMPPF

8
Radient Technologies - Excellent Growth Expected Over The Next Few Years

2018-05-05 seekingalpha
Radient continues to see steady revenue growth. The company also has excellent cash on hand to continue to grow its operations.
ACB ACBFF RTI RDDTF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...